ICU MEDICAL INC/DE ICUI revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ICU MEDICAL INC/DE reported revenue across 3 products and services; the largest, Infusion Consumables, was $1.11B, 49.7% of the filed sum (+6.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Infusion Consumables$1.11B49.7%+6.8% yoy
- Infusion Systems$684M30.7%+4.9% yoy
- Vital Care$438M19.6%-36.6% yoy
Members sum to the consolidated $2.23B for this period.
- United States$1.36B60.8%-11.5% yoy
- EMEA$412M18.5%+4.6% yoy
- APAC$233M10.4%0.0% yoy
- Otherforeigncountries$231M10.3%+3.1% yoy
Members sum to the consolidated $2.23B for this period.
- Infusion Consumables$278M52.5%+4.5% yoy
- Infusion Systems$180M33.9%+8.0% yoy
- Vital Care$72.3M13.6%-58.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.